Nanomedicine and Liver Cancer Stem Cells

VIEWS - 281 (Abstract) 96 (PDF)
Ling Bai, Cheng Jin


In recent years, overwhelming experimental and clinical data demonstrate the existence of a unique subpopulation of highly malignant tumor cells termed as cancer stem cells (CSCs). They have been found in many solid tumors, including liver cancer. Liver CSCs may be known as the source of malignant cells, the reason for resistance to chemotherapy and radiotherapy, and the cells source of distant metastases. Therefore, new and effective treatment strategies targeting liver CSCs are urgently needed. Nanomedicine-based nanotechniques and biomaterials have emerged as some of the most promising carrier systems for medical imaging and drug delivery. The advances of nanomedicine result in the concept of precision medicine and the opportunity for early diagnoses and highly-effective targeted therapy. This review will focus on the properties of liver CSCs, discuss the preclinical and clinical available applications of nanomedicine, and explore the future implications and challenges.

Full Text:

Download PDF


Visvader JE, 2011, Cells of Origin in Cancer. Nature, 469(7330):314–22.

Visvader JE, Lindeman GJ, 2012, Cancer Stem Cells: Current Status and Evolving Complexities. Cell Stem Cell, 10(6):717–28. DOI: 10.1016/j.stem.2012.05.007.

Batlle E, Clevers H, 2017, Cancer Stem Cells Revisited. Nat Med, 23(10):1124–34. DOI: 10.1038/nm.4409.

Chang JC, 2016, Cancer Stem Cells: Role in Tumor Growth, Recurrence, Metastasis, and Treatment Resistance. Medicine (Baltimore), 95(1):S20–5. DOI: 10.1097/ md.0000000000004766.

Yagci T, Cetin M, Ercin PB, 2017, Cancer Stem Cells in Hepatocellular Carcinoma. J Gastrointest Cancer, 48(3):241–5. DOI: 10.1007/s12029-017-9960-7.

Wang K, Sun D, 2018, Cancer Stem Cells of Hepatocellular Carcinoma. Oncotarget, 9(33):23306–14.

Nio K, Yamashita T, Kaneko S, 2017, The Evolving Concept of Liver Cancer Stem Cells. Mol Cancer, 16(1):4. DOI: 10.1186/s12943-016-0572-9.

Forner A, Llovet JM, Bruix J, 2012, Hepatocellular Carcinoma. Lancet, 379(9822):1245–55. DOI: 10.1016/ s0140-6736(11)61347-0.

Kudo M, 2017, Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. Oncology, 93(1):135–46.

Oishi N, Wang XW, 2011, Novel Therapeutic Strategies for Targeting Liver Cancer Stem Cells. Int J Biol Sci, 7(5):517–35.

Ochiya T, 2016, Novel Therapeutic Strategies Targeting Liver Cancer Stem Cells. Chin Clin Oncol, 5(5):59. DOI: 10.21037/cco.2016.03.10.

Zhou G, Wilson G, George J, et al., 2015, Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer. Curr Gene Ther, 15(2), 161–70.

Zou GM, 2010, Liver Cancer Stem Cells as an Important Target in Liver Cancer Therapies. Anticancer Agents Med Chem, 10(2):172–5. DOI: 10.2174/187152010790909263.

Machida K, 2017, Existence of Cancer Stem Cells in Hepatocellular Carcinoma: Myth or Reality? Hepatol Int, 11(2):143–7. DOI: 10.2174/187152010790909263.

Xiang Y, Yang T, Pang BY, et al., 2016, The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma. Stem Cells Int, 2016:7614971. DOI: 10.1155/2016/7614971.

Xiao Y, Lin M, Jiang X, et al., 2017, The Recent Advances on Liver Cancer Stem Cells: Biomarkers, Separation, and Therapy. Anal Cell Pathol (Amst), 2017:5108653.

Talukdar S, Emdad L, Das SK, et al., 2016, Evolving Strategies for Therapeutically Targeting Cancer Stem Cells. Adv Cancer Res, 131:159–91. DOI: 10.1016/bs.acr.2016.04.003.

Kuhlmann JD, Hein L, Kurth I, et al., 2016, Targeting Cancer Stem Cells: Promises and Challenges. Anticancer Agents Med Chem, 16(1):38–58. DOI: 10.2174/187152061 5666150716104152.

Shigdar S, Lin J, Li Y, et al., 2012, Cancer Stem Cell Targeting: The Next Generation of Cancer Therapy and Molecular Imaging. Ther Deliv, 3(2):227–44.

Garvalov BK, Acker T, 2011, Cancer Stem Cells: A New Framework for the Design of Tumor Therapies. J Mol Med, 89(2), 95–107. DOI: 10.1007/s00109-010-0685-3.

Caruthers SD, Wickline SA, Lanza GM, 2007, Nanotechnological Applications in Medicine. Curr Opin Biotechnol, 18(1):26–30.

Wang X, Yang L, Chen ZG, et al., 2008, Application of Nanotechnology in Cancer Therapy and Imaging. CA Cancer J Clin, 58(2):97–110.

Yameen B, Choi WI, Vilos C, et al., 2014, Insight Into Nanoparticle Cellular Uptake and Intracellular Targeting. J Control Release, 190:485–99. DOI: 10.1016/j. jconrel.2014.06.038.

Heath JR, 2015, Nanotechnologies for Biomedical Science and Translational Medicine. Proc Natl Acad Sci USA, 112(47):14436–43. DOI: 10.1073/pnas.1515202112.

Bazak R, Houri M, EI Achy S, et al., 2015, Cancer Active Targeting by Nanoparticles: A Comprehensive Review of Literature. J Cancer Res Clin Oncol, 141(5):769–84. DOI: 10.1007/s00432-014-1767-3.

Baetke SC, Lammers T, Kiessling F, 2015, Applications of Nanoparticles for Diagnosis and Therapy of Cancer. Br J Radiol, 88(1054):20150207. DOI: 10.1259/bjr.20150207.

Amin ML, Joo JY, Yi DK, et al., 2015, Surface Modification and Local Orientations of Surface Molecules in Nanotherapeutics. J Control Release, 207:131–42. DOI: 10.1016/j.jconrel.2015.04.017.

Thakor AS, Gambhir SS, 2013, Nanooncology: The Future of Cancer Diagnosis and Therapy. CA Cancer J Clin, 63(6):395–418. DOI: 10.3322/caac.21199.

Weissleder R, 2006, Molecular Imaging in Cancer. Science, 312(5777):1168–71.

Kjaer A, 2006, Molecular Imaging of Cancer Using PET and SPECT. Adv Exp Med Biol, 587:277–84.

Iagaru A, Masamed R, Keesara S, et al., 2007, Breast MRI and 18F FDG PET/CT in the Management of Breast Cancer. Ann Nucl Med, 21(1):33–8. DOI: 10.1007/bf03033997.

Saadeh Y, Leung T, Vyas A, et al., 2014, Applications of Nanomedicine in Breast Cancer Detection, Imaging, and Therapy. J Nanosci Nanotechnol, 14(1):913–23. DOI: 10.1166/jnn.2014.8755.

Bennett KM, Jo J, Cabral H, et al., 2014, MR Imaging Techniques for Nano-pathophysiology and Theranostics. Adv Drug Deliv Rev, 74:75–94. DOI: 10.1016/j.addr.2014.04.007.

Bhise K, Sau S, Alsaab H, et al., Nanomedicine for Cancer Diagnosis and Therapy: Advancement, Success and Structure-activity Relationship. Ther Deliv, 8(11):1003–18.

Winter PM, Neubauer AM, Caruthers SD, et al., 2006, Endothelial Alpha(v)Beta3 Integrin-targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis. Arterioscler Thromb Vasc Biol, 26(9):2103–9.

Bogart LK, Pourroy G, Murphy CJ, et al., 2014, Nanoparticles for Imaging, Sensing, and Therapeutic Intervention. ACS Nano, 8(4):3107–22. DOI: 10.1021/nn500962q.

Hong IS, Jang GB, Lee HY, et al., 2015, Targeting Cancer Stem Cells by Using the Nanoparticles. Int J Nanomedicine, 10: 251–60.

Shi AM, Tao ZQ, Li H, et al., Cancer Stem Cells Targeting Agents--a Review. Eur Rev Med Pharmacol Sci, 19(21):4064–7.

Lang J, Lan X, Liu Y, et al., 2015, Targeting Cancer Stem Cells with an 131I-labeled Anti-AC133 Monoclonal Antibody in Human Colorectal Cancer Xenografts. Nucl Med Biol, 42(5):505–12. DOI: 10.1016/j.nucmedbio.2015.01.003.

Barbato L, Bocchetti M, Di Biase A, et al., 2019, Cancer Stem Cells and Targeting Strategies. Cells, 8(8):E926. DOI: 10.3390/cells8080926.

Dawood S, Austin L, Cristofanilli M, 2014, Cancer Stem Cells: Implications for Cancer Therapy. Oncology, 28(12):1101–7, 1110.

Kafshgari MH, Harding FJ, Voelcker NH, 2015, Insights Into Cellular Uptake of Nanoparticles. Curr Drug Deliv, 12(1):63–77. DOI: 10.2174/1567201811666140821110631.

Chen H, Gao J, Lu Y, et al., 2008, Preparation and Characterization of PE38KDEL-loaded anti- HER2 Nanoparticles for Targeted Cancer Therapy. J Control Release, 128(3):209–16. DOI: 10.1016/j. jconrel.2008.03.010.

Jin C, Bai L, Wu H, et al., 2007, Radiosensitization of Paclitaxel, Etanidazole and Paclitaxel+Etanidazole Nanoparticles on Hypoxic Human Tumor Cells In Vitro. Biomaterials, 28(25):3724–30. DOI: 10.1016/j. biomaterials.2007.04.032.

Jin C, Bai L, Wu H, et al., 2009, Cytotoxicity of Paclitaxel Incorporated in PLGA Nanoparticles on Hypoxic Human Tumor Cells. Pharm Res, 26(7):1776–84. DOI: 10.1007/ s11095-009-9889-z.

Jin C, Bai L, Lin L, et al., 2018, Paclitaxel-loaded Nanoparticles Decorated with Bivalent Fragment HAb18 F(ab’)2 and Cell Penetrating Peptide for Improved Therapeutic Effect on Hepatocellular Carcinoma. Artif Cells Nanomed Biotechnol, 46(5):1076–84. DOI: 10.1080/21691401.2017.1360325.

Zhao H, Wu M, Zhu L, et al., 2018, Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma. Theranostics, 8(7):1892–910. DOI: 10.7150/thno.22386.

Stephan MT, Moon JJ, Um SH, et al., 2010, Therapeutic Cell Engineering with Surface-conjugated Synthetic Nanoparticles. Nat Med, 16(9):1035–41. DOI: 10.1038/nm.2198.

Rao W, Wang H, Zhong A, et al., 2016, Nanodrug-mediated Thermotherapy of Cancer Stem-like Cells. J Nanosci Nanotechnol, 16(3):2134–42. DOI: 10.1166/ jnn.2016.10942.

Valencia PM, Hanewich-Hollatz MH, Gao W, et al., 2011, Effects of Ligands with Different Water Solubilities on Self-assembly and Properties of Targeted Nanoparticles. Biomaterials, 32(26):6226–33. DOI: 10.1016/j. biomaterials.2011.04.078.

Qin W, Huang G, Chen Z, et al., 2017, Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy. Front Pharmacol, 8:1–15. DOI: 10.3389/fphar.2017.00001.

Swaminathan SK, Roger E, Toti U, et al., 2013, CD133- targeted Paclitaxel Delivery Inhibits Local Tumor Recurrence in a Mouse Model of Breast Cancer. J Control Release, 171(3):280–7. DOI: 10.1016/j.jconrel.2013.07.014.

Sapra P, Tyagi P, Allen TM, 2005, Ligand-targeted Liposomes for Cancer Treatment. Curr Drug Deliv, 2(4):369–81. DOI: 10.2174/156720105774370159.

Gong Z, Chen D, Xie F, et al., 2016, Codelivery of Salinomycin and Doxorubicin using Nanoliposomes for Targeting Both Liver Cancer Cells and Cancer Stem Cells. Nanomedicine (Lond), 11(19):2565–79. DOI: 10.2217/ nnm-2016-0137.

Wang Z, Tan J, McConville C, et al., 2017, Poly Lactic-co-glycolic Acid Controlled Delivery of Disulfiram to Target Liver Cancer Stem-like Cells. Nanomedicine, 13(2):641–57. DOI: 10.1016/j.nano.2016.08.001.

Wang M, Xie F, Wen X, et al., 2017, Therapeutic PEG-ceramide Nanomicelles Synergize with Salinomycin to Target Both Liver Cancer Cells and Cancer Stem Cells. Nanomedicine (Lond), 12(9):1025–42. DOI: 10.2217/nnm- 2016-0408.

Jin C, Bai L, Li H, et al., 2013, Paclitaxel-loaded Nanoparticles Decorated with Anti-CD133 Antibody for Targeting Liver Cancer Stem Cells. J Control Release, 172(2):e20–1. DOI: 10.1016/j.jconrel.2013.08.049.

Jin C, Yang Z, Yang J, et al., 2014, Paclitaxel-loaded Nanoparticles Decorated with Anti-CD133 Antibody: A Targeted Therapy for Liver Cancer Stem Cells. J Nanopart Res, 16(1):2157–71. DOI: 10.1007/s11051-013-2157-5.

Jordan CT, Guzman ML, Noble M, 2006, Cancer Stem Cells. N Engl J Med, 355(12):1253–61.



  • There are currently no refbacks.

Copyright (c) 2019 Bai and Jin

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Recent Articles | About Journal | For Author | Fees | About Whioce

Copyright © Whioce Publishing Pte Ltd. All Rights Reserved.